Name: Advanced breast cancer: T-DM1 a double whammy against the tumor (en Inglés)
SKU: 58033329
Price: 172448.00 COP
Availability: InStock
Author: Bensaber, Hayette Sénia ; El Kebir, Fatima Zohra
ISBN: 9786203607000

portada Advanced breast cancer: T-DM1 a double whammy against the tumor (en Inglés)

Advanced breast cancer: T-DM1 a double whammy against the tumor (en Inglés)

Formato

Libro Físico

Autor

Hayette Sénia Bensaber

Fatima Zohra El Kebir

Editorial

Our Knowledge Publishing

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

Dimensiones

22.9x15.2x0.4 cm

Peso

0.10 kg.

ISBN13

9786203607000

Categorías

Medicina clínica e interna

Advanced breast cancer: T-DM1 a double whammy against the tumor (en Inglés)

Hayette Sénia Bensaber (Autor) · Fatima Zohra El Kebir (Autor) · Our Knowledge Publishing · Tapa Blanda

Libro Nuevo Importado

Envío: 21 a 25 días háb.

$ 313.541$ 172.448

-45%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 10 unidades

$ 172.448

¡Envío Gratis! Llega entre el 16 Sep y el 23 Sep a Bogota, Cundinamarca. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Advanced breast cancer: T-DM1 a double whammy against the tumor (en Inglés)"

RESUMET-DM1 is the first of an experimental new cancer drug known as an antibody-drug conjugate. It demonstrates an improvement in progression-free survival over standard therapy in HER2-positive metastatic breast cancer. It combines two existing cancer drugs in order to deliver both drugs specifically to cancer cells: Trastuzumab, a monoclonal antibody to target cells that overproduce the HER2 protein; and, T-DM1 is a chemotherapeutic substance.This is the first ever presentation of an anti-HER2 antibody-drug conjugate used as a primary treatment for patients with advanced breast cancer," said Professor Perez. "We are encouraged by the results. The study explained that T-DM1 has very good anti-tumor activity as well as much lower toxicity when evaluated side-by-side to the older "standard". T-DM1 has displayed promising activity in preclinical studies.